Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 6/20 | 0.43 |
| ▸ | FPR3 | P25089 | 5/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983281 | 0.89 | MEN1 (0.52) | RORCOPRD1OPRK1JAK2JAK1 | |
| SCHEMBL4630446 | 0.84 | RORC (0.50) | RORCOPRD1OPRK1JAK2JAK1 | |
| SCHEMBL16764525 | 0.83 | RORC (0.53) | RORCJAK2JAK1FPR2FPR3 | |
| SCHEMBL1199600 | 0.83 | RORC (0.51) | RORCOPRD1OPRK1JAK2JAK1 | |
| SCHEMBL4629887 | 0.82 | TSHR (0.49) | RORCOPRD1OPRK1JAK2JAK1 | |
| SCHEMBL1981622 | 0.82 | GPR119 (0.47) | RORCOPRD1OPRK1JAK2JAK1 | |
| SCHEMBL1200040 | 0.82 | RORC (0.53) | RORCJAK2JAK1FPR2FPR3 | |
| SCHEMBL19459178 | 0.81 | ESR2 (0.48) | RORCOPRD1OPRK1ESR2GPR119 | |
| SCHEMBL18432250 | 0.81 | ESR2 (0.48) | OPRD1OPRK1ESR2GPR119TSHR | |
| SCHEMBL1978754 | 0.81 | GPR119 (0.50) | RORCOPRD1OPRK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-1933832-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1902032-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | RORC 315/4885OPRD1 412/4885OPRK1 254/4885 |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, GRK2 | RORC 42/4885OPRD1 119/4885OPRK1 67/4885 |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, ERBB3, NCOA3 | RORC 204/4885OPRD1 418/4885OPRK1 232/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | RORC 315/4885OPRD1 412/4885OPRK1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.